Malaria Drug Pipeline Examined in New In-demand PNS Pharma Report Recently Published at

29 Aug 2013 • by Natalie Aster

LONDON – Malaria causes a large number of deaths annually. For instance, the number of malaria-caused deaths stood at approximately 595,000 in 2011, with over 85% of the deaths reported in Africa. However, the mortality dropped to a certain extent over the last decade owing to advances in the healthcare industry.

At present, some of the most common antimalarian drugs include Qualaquin, Aralen, Mefloquine, among others. Besides, there are medicines under different development stages such as Centanamycin and GlaxoSmithKline, to name a few.

New in-demand research report “Malaria Disease Drug Pipeline Analysis” developed by PNS Pharma delves deep into the malaria disease drug pipeline. The study offers an insightful discussion of ongoing development of the drugs, including data on different development phases. Besides, the research study comprises detailed drug profiles including information on originator, owner, chemical formula, country of development, brand names, patent information, among others.

Report Details:

Malaria Disease Drug Pipeline Analysis
Published: August, 2013
Pages: 185
Price: US$ 1,200.00

Other Diseases Drug Pipeline Analyses by PNS Pharma Include:

More new market research reports by the publisher can be found at PNS Pharma page.


The Market Publishers, Ltd.
Tanya Levdikova
Tel: +44 208 144 6009
Fax: +44 207 900 3970